Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
Status:
Terminated
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia
(CLI), which is the most severe form of peripheral arterial disease (PAD). This trial is
designed to assess the efficacy and safety of the drug in the treatment of CLI.